  Quinze ans d'anti-TNF dans la maladie de Crohn: comment tirer le meilleur de cette revolution therapeutique?Louis, Edouard  ; REENAERS, Catherine ; Meuwis, Marie-Alice et alin Revue Médicale de Liège (2012), 67 Spec No After fifteen years of use, the anti-TNF antibodies have become the corner stone of the treatment of moderate and severe Crohn's disease. The skill acquired over the years through experimental trials and ... [more ▼] After fifteen years of use, the anti-TNF antibodies have become the corner stone of the treatment of moderate and severe Crohn's disease. The skill acquired over the years through experimental trials and clinical experience leads to increased therapeutic efficacy and minimized risks. These antibodies are introduced increasingly earlier in Crohn's disease as well as in a broader range of patients, aiming at changing the natural history of the diseases by avoiding the development of intestinal tissue damage and complications. [less ▲] Detailed reference viewed: 16 (2 ULg)Les thérapies innovantes au CHU dans les maladies inflammatoires chroniques de l'intestin (MICI)Belaiche, Jacques ; Chapelier, Nathalie ; Wertz, Sylvie et alin Revue Médicale de Liège (2007), 62 Spec No Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis are frequent illnesses in western countries. They have a dramatic impact on the health-related quality of life. The new biological ... [more ▼] Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis are frequent illnesses in western countries. They have a dramatic impact on the health-related quality of life. The new biological treatments developed for these diseases are potentially very effective, but are also expensive and may have significant side effects. In the present paper, the authors describe new biological therapies used during the past 10 years at the CHU. More than 20 therapeutic protocols were implemented. These protocols have given the patients the opportunity to gain very rapid access to new efficient therapies, to benefit from promising techniques for the evaluation of their pathology and to be submitted to a close follow-up that frequently called their treatment into question in the light of the most innovative options. [less ▲] Detailed reference viewed: 82 (2 ULg) Interleukin-6: An osteotropic factor influencing bone formation?; Wertz, Sylvie ; Malaise, Michel in BONE (2005), 37(5), 601-606 Interleukin (IL)-6 has long been considered as an osteoresorptive factor. However, recent data indicate that IL-6 could influence bone formation in conditions of increased bone turnover. In this paper ... [more ▼] Interleukin (IL)-6 has long been considered as an osteoresorptive factor. However, recent data indicate that IL-6 could influence bone formation in conditions of increased bone turnover. In this paper, the effects of IL-6 and its soluble receptor on osteoblast proliferation, differentiation and apoptosis are readdressed. A brief summary of IL-6 signaling after binding to its receptor is provided and hypotheses concerning IL-6 and the central control of bone formation are also highlighted. (c) 2005 Elsevier Inc. All rights reserved. [less ▲] Detailed reference viewed: 3 (0 ULg) |
||
